You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Guidelines & Advice
About Guidelines Email Guidelines Team

The Use of Leucovorin in Colorectal Cancer

ID: 12-17 Feb 2016
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: Archived
Authors:
J.J. Biagi, N. Coakley, C. Earle, C. Erlichman, A. Fields

Guideline Objective

The objective of this evidence summary was to examine evidence regarding outcomes associated with different doses of leucovorin (LV) for the treatment of colorectal cancer (CRC) patients.

Patient Population

Patients with CRC, any stage, and treatment in the adjuvant or advanced setting, as part of a trial that compares different doses of LV in combination with 5-FU chemotherapy.

Intended Guideline Users

  1. Clinicians and pharmacists involved in the prescription and preparation of LV with 5-FU chemotherapy.
  2. Cancer Care Ontario (CCO) Systemic Treatment Program

Research Question(s)

What is the effect of altering the dose of LV for patients with CRC in terms of overall survival, progression-free survival (PFS), disease-free survival, response rate, and adverse events/toxicity, given a constant dose of 5-fluorouracil (5-FU)?

pdf download Full Report (PDF) (586.43 KB)